Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus ("HBV") infection. We are advancing multiple product candidates with distinct mechanisms of action that we believe have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include the following programs: RNAi, Capsid Inhibitor, HBV RNA Destabilizers and additional pre-clinical assets.
September 21 2021
September 7 2021